Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.870
+0.050 (1.77%)
At close: Nov 14, 2025, 4:00 PM EST
2.961
+0.091 (3.17%)
After-hours: Nov 14, 2025, 7:59 PM EST
Lipocine Revenue
Lipocine had revenue of $622.85K in the quarter ending June 30, 2025, with 595.42% growth. This brings the company's revenue in the last twelve months to $4.32M, down -45.44% year-over-year. In the year 2024, Lipocine had annual revenue of $11.20M, down -492.80%.
Revenue (ttm)
$4.32M
Revenue Growth
-45.44%
P/S Ratio
3.56
Revenue / Employee
$270,168
Employees
16
Market Cap
15.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.20M | 14.05M | -492.80% |
| Dec 31, 2023 | -2.85M | -3.35M | -670.16% |
| Dec 31, 2022 | 500.00K | -15.64M | -96.90% |
| Dec 31, 2021 | 16.14M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LPCN News
- 10 days ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 12 days ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire
- 6 weeks ago - Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 - PRNewsWire
- 3 months ago - Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PRNewsWire
- 5 months ago - Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - PRNewsWire
- 5 months ago - Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - PRNewsWire